Topoisomerase II alpha and microtubuleassociated protein-tau as a predictive marker in axillary lymph node positive breast cancer

Tumori

Volumn 100, Issue 1, 2014, Pages 80-86

  Won, Hye Sung ^a   Lee, Kyoung Eun ^b   Sung, Sun Hee ^c   Choi, Moon Young ^d   Jo, Jung Youn ^b   Nam, Eun Mi ^b   Mun, Yeung Chul ^b   Seong, Chu Myong ^b   Lee, Soon Nam ^b  

^a The Catholic University of Korea   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Ewha Womans University School of Medicine   (South Korea)

^d Inje University   (South Korea)

Author keywords

Anthracycline; Breast cancer; Microtubule associated protein tau; Taxane; Topoisomerase II alpha

Indexed keywords

ANTHRACYCLINE; DNA TOPOISOMERASE (ATP HYDROLYSING); HORMONE RECEPTOR; TAU PROTEIN; TAXANE DERIVATIVE; TOPOISOMERASE II ALPHA; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CARCINOMA, MEDULLARY; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TAU PROTEINS; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84896993435     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/1430.15820     Document Type: Article

References (22)

1. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet, 352: 930-942, 1998.
2. De Laurentiis M, Cancello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Espiosito A, Silvestro L, Pennacchio R, Criscitiello C, Montanino A, Limite G, Bianco AR, De Placido S: Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol, 26: 44-53, 2008.
3. Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, Bruzzi P: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst, 100: 14-20, 2008.
4. Di Leo A, Biganzoli L, Claudino W, Licitra S, Pestrin M, Larsimont D: Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime? Eur J Cancer, 44: 2791-2798, 2008.
5. Rody A, Karn T, Ruckhaberle E, Muller V, Gehrmann M, Solbach C, Ahr A, Gätje R, Holtrich U, Kaufmann M: Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer. Breast Cancer Res Treat, 113: 457-466, 2009.
6. O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman D, Bramwell VH, Andrulis IL, Pritchard KI: Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial. Breast Cancer Res Treat, 128: 401-409, 2011.
7. Pusztai L: Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. Ann Oncol, 18 (suppl 12): xii15-20, 2007.
8. Wagner P, Wang B, Clark E, Lee H, Rouzier R, Pusztai L: Microtubule associated protein (MAP)-tau: a novel mediator of paclitaxel sensitivity in vitro and in vivo. Cell Cycle, 4: 1149-1152, 2005.
9. Andre F, Hatzis C, Anderson K, Sotiriou C, Mazouni C, Mejia J, Wang B, Hortobagyi GN, Symmans WF, Pusztai L: Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res, 13: 2061-2067, 2007.
10. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ; Panel members: Strategies for subtypesdealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol, 22: 1736-1747, 2011.
11. Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, Hannon GJ, Lowe SW, Hemann MT: Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A, 105: 9053-9058, 2008.
12. Corzo C, Bellosillo B, Corominas JM, Salido M, Coll MD, Serrano S, Albanell J, Solé F, Tusquets I: Does polysomy of chromosome 17 have a role in ERBB2 and topoisomerase II alpha expression? Gene, mRNA and protein expression: a comprehensive analysis. Tumour Biol, 28: 221-228, 2007.
13. Arriola E, Rodriguez-Pinilla SM, Lambros MB, Jones RL, James M, Savage K, Smith IE, Dowsett M, Reis-Filho JS: Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat, 106: 181-189, 2007.
14. Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O'Mally FP, Cardoso F, Tanner M, Munro A, Twelves CJ, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M; HER2/TOP2A Meta-analysis Study Group: HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol, 12: 1134-1142, 2011.
15. Desmedt C, Di Leo A, de Azambuja E, Larsimont D, Haibe-Kains B, Selleslags J, Delaloge S, Duhem C, Kains JP, Carly B, Maerevoet M, Vindevoghel A, Rouas G, Lallemand F, Durbecq V, Cardoso F, Salgado R, Rovere R, Bontempi G, Michiels S, Buyse M, Nogaret JM, Qi Y, Symmans F, Pusztai L, D'Hondt V, Piccart-Gebhart M, Sotiriou C: Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol, 29: 1578-1586, 2011.
16. Rody A, Karn T, Gatje R, Ahr A, Solbach C, Kourtis K, Munnes M, Loibl S, Kissler S, Ruckhäberle E, Holtrich U, von Minckwitz G, Kaufmann M: Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubuleassociated protein tau, is highly predictive of tumor response. Breast, 16: 86-93, 2007.
17. Durbecq V, Paesmans M, Cardoso F, Desmedt C, Di Leo A, Chan S, Friedrichs K, Pinter T, Van Belle S, Murray E, Bodrogi I, Walpole E, Lesperance B, Korec S, Crown J, Simmonds P, Perren TJ, Leroy JY, Rouas G, Sotiriou C, Piccart M, Larsimont D: Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol Cancer Ther, 3: 1207-1214, 2004.
18. Martin-Richard M, Munoz M, Albanell J, Colomo L, Bellet M, Rey MJ, Tabernero J, Alonso C, Cardesa A, Gascon P, Fernandez PL: Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracyclinebased chemotherapy. Oncology, 66: 388-394, 2004.
19. Petit T, Wilt M, Velten M, Millon R, Rodier JF, Borel C, Mors R, Haegelé P, Eber M, Ghnassia JP: Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer, 40: 205-211, 2004.
20. Depowski PL, Rosenthal SI, Brien TP, Stylos S, Johnson RL, Ross JS: Topoisomerase II alpha expression in breast cancer: correlation with outcome variables. Mod Pathol, 13: 542-547, 2000.
21. Nakopoulou L, Lazaris AC, Kavantzas N, Alexandrou P, Athanassiadou P, Keramopoulos A, Davaris P: DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer. Pathobiology, 68: 137-143, 2000.
22. Baquero MT, Lostritto K, Gustavson MD, Bassi KA, Appia F, Camp RL, Molinaro AM, Harris LN, Rimm DL: Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts. Breast Cancer Res, 13: R85, 2011.